 |
12 Diseases |  |
7 Trials |
|
7 Trials |  |
180 News |  |
| «123 |
- Duvie (lobeglitazone) / Chong Kun Dang
Trial primary completion date: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (clinicaltrials.gov) - Nov 27, 2016
P4, N=190, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Aug 2016 --> Dec 2016
- Duvie (lobeglitazone) / Chong Kun Dang
Trial primary completion date: Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) - Aug 23, 2016
P4, N=120, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Dec 2016
- | Duvie (lobeglitazone) / Chong Kun Dang
Clinical: Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin (clinicaltrials.gov) - Aug 3, 2016
P1, N=30, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | lobeglitazone/sitagliptin (CKD-396) / Chong Kun Dang, Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1) (clinicaltrials.gov) - Jul 11, 2016
P1, N=20, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | lobeglitazone/sitagliptin (CKD-396) / Chong Kun Dang, Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1) (clinicaltrials.gov) - Jul 7, 2016
P1, N=20, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
Trial completion, Trial primary completion date: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function (clinicaltrials.gov) - Jul 5, 2016
P1, N=26, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: May 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: May 2016 --> Feb 2016
- Duvie (lobeglitazone) / Chong Kun Dang
Enrollment change, Trial primary completion date: Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) - May 3, 2016
P4, N=120, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Completed | Trial primary completion date: May 2016 --> Feb 2016 N=50 --> 120 | Trial primary completion date: Feb 2016 --> May 2016
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers (clinicaltrials.gov) - Feb 21, 2016
P1, N=26, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
Trial completion, Enrollment change: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD (clinicaltrials.gov) - Feb 2, 2016
P4, N=38, Completed, Sponsor: Yonsei University
N=50 --> 120 | Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed | N=50 --> 38
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers (clinicaltrials.gov) - Jan 7, 2016
P1, N=26, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers (clinicaltrials.gov) - Dec 10, 2015
P1, N=26, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- Duvie (lobeglitazone) / Chong Kun Dang
Trial primary completion date: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (clinicaltrials.gov) - Oct 27, 2015
P4, N=190, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Completed | N=50 --> 38 Trial primary completion date: Aug 2015 --> Aug 2016
- Duvie (lobeglitazone) / Chong Kun Dang
Enrollment open, Trial primary completion date: Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) - Oct 27, 2015
P4, N=50, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Aug 2015 --> Aug 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Feb 2016
- Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Combination therapy: Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) - Oct 26, 2015
P4, N=78, Recruiting, Sponsor: Seoul National University Bundang Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Feb 2016 Not yet recruiting --> Recruiting
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers (clinicaltrials.gov) - Oct 1, 2015
P1, N=26, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- ||||| Duvie (lobeglitazone) / Chong Kun Dang
New P4 trial: Efficacy and Safety of Lobeglitazone Versus Sitagliptin (clinicaltrials.gov) - Jun 24, 2015
P4, N=248, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
Enrollment open, Trial primary completion date: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD (clinicaltrials.gov) - Feb 9, 2015
P4, N=50, Recruiting, Sponsor: Yonsei University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- | Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Combination therapy: Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) - Jan 15, 2015
P4, N=78, Not yet recruiting, Sponsor: Seoul National University Bundang Hospital
- | Duvie (lobeglitazone) / Chong Kun Dang
New P4 trial: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (clinicaltrials.gov) - Dec 11, 2014
P4, N=190, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Duvie (lobeglitazone) / Chong Kun Dang
New P4 trial: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD (clinicaltrials.gov) - Nov 6, 2014
P4, N=50, Not yet recruiting, Sponsor: Yonsei University
- Duvie (lobeglitazone) / Chong Kun Dang
Enrollment open: Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=38, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- Duvie (lobeglitazone) / Chong Kun Dang
New P4 trial: Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) - Jul 12, 2014
P4, N=50, Not yet recruiting, Sponsor: Seoul National University Bundang Hospital
- | Duvie (lobeglitazone) / Chong Kun Dang
Trial completion: Drug-drug Interaction Study(Lobeglitazone, Warfarin) (clinicaltrials.gov) - Jul 3, 2014
P1, N=24, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Duvie (lobeglitazone) / Chong Kun Dang
Trial primary completion date: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function (clinicaltrials.gov) - May 20, 2014
P1, N=24, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Completed Trial primary completion date: Nov 2015 --> May 2016
- Duvie (lobeglitazone) / Chong Kun Dang
Trial completion date: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function (clinicaltrials.gov) - May 20, 2014
P1, N=24, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Nov 2015 --> May 2016 Trial completion date: Dec 2015 --> May 2016
- Duvie (lobeglitazone) / Chong Kun Dang
Enrollment open: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function (clinicaltrials.gov) - May 20, 2014
P1, N=24, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial completion date: Dec 2015 --> May 2016 Not yet recruiting --> Recruiting
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects (clinicaltrials.gov) - Dec 9, 2013
P1, N=38, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function (clinicaltrials.gov) - Dec 5, 2013
P1, N=24, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Duvie (lobeglitazone) / Chong Kun Dang
New P1 trial: Drug-drug Interaction Study(Lobeglitazone, Warfarin) (clinicaltrials.gov) - Dec 4, 2013
P1, N=24, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||||||| Duvie (lobeglitazone) / Chong Kun Dang
Trial completion: Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin (clinicaltrials.gov) - Feb 12, 2013
P3, N=253, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Duvie (lobeglitazone) / Chong Kun Dang
Trial completion: An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 7, 2012
P3, N=173, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed
- | Duvie (lobeglitazone) / Chong Kun Dang
Trial completion: Drug-drug Interaction Study(CKD-501, Amlodipine) (clinicaltrials.gov) - Aug 11, 2011
P1, N=25, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Active, not recruiting --> Completed Active, not recruiting --> Completed